Giulia KennedyPhD
VeracyteChapter 08 · Strand B · Achievement

Veracyte goes public

Veracyte priced its initial public offering on October 30, 2013 at $13.00 a share and began trading on NASDAQ as VCYT, five years after Kennedy joined as its first executive hire.

OCT 2013 – NOV 2013CHIEF SCIENTIFIC OFFICER, VERACYTEVERACYTE, INC. · SOUTH SAN FRANCISCO, CALIFORNIA

Overview

Five and a half years after Kennedy joined as its first executive hire, Veracyte became a public company. On October 30, 2013 it priced an initial public offering of 5,000,000 shares of common stock at $13.00 per share and began trading on the NASDAQ Global Market under the symbol VCYT.1 The offering closed on November 4, 2013.2

Context

The registration statement filed ahead of the offering is the most detailed primary record of Kennedy’s career to that point. It lists her among the company’s executive officers and sets out her roles: Senior Vice President of Research and Development from April 2008, Chief Scientific Officer from September 2008, and before Veracyte a Senior Director at Affymetrix from January 2000 to March 2008, with earlier scientific roles at Chiron Corporation and Millennium Pharmaceuticals.3 Much of the dating on this site rests on that filing.

At the time of the offering Veracyte had one commercial product, the Afirma thyroid test launched in January 2011; the lung tests that followed were still in development.4

Why it matters here

The IPO marks the point at which the science Kennedy’s team had built became the basis of a public company, and from which her work is documented in annual reports and proxy statements as well as journals.

From the record

Facts

  • Veracyte priced an initial public offering of 5,000,000 shares of common stock at $13.00 per share on October 30, 2013 and began trading on the NASDAQ Global Market under the symbol VCYT that day.1
  • The offering closed on November 4, 2013.2
  • Kennedy was named as an executive officer in the Form S-1 registration statement, which records her roles since April 2008.3

Achievements

  1. 30 OCT 2013milestone

    Veracyte initial public offering

    Veracyte priced an initial public offering of 5,000,000 shares at $13.00 per share and began trading on the NASDAQ Global Market under the symbol VCYT; the offering closed on November 4, 2013.123

Impact

  • VERACYTE INITIAL PUBLIC OFFERING

    Kennedy was an executive officer named in the registration statement.

Impact across the career